

Delayed Foreign Body Granulomas in the Orofacial Region after Hyaluronic Acid Injection

Fang Fei ZHANG^{1,2}, Zhi Xiu XU¹, Yan CHEN¹

Objective: To evaluate and analyse granulomatous reaction caused by intradermal injections with hyaluronic acid (HA) fillers in the orofacial region.

Methods: A retrospective review of 11 cases of foreign body granulomas caused by HA fillers was performed. Demographic data, clinical symptoms, imaging features, treatments, pathology results, history of facial cosmetic procedures and prognosis were reviewed.

Results: Most of the cases appeared as painless palpable nodules with no significant growth, located in the cheeks, chin, lips or temples. The nodules were excised, and pathological examination revealed amorphous basophilic material surrounded by foreign body giant cells and macrophages. No patient's clinical and pathological diagnosis was linked to HA during the first appointment. During follow-up, all patients admitted that they had received dermal filler injections from 3 to 10 years previously. Most of the patients had a favourable prognosis; one patient complained of facial asymmetry and another reported mild pain in the upper lip after surgery.

Conclusion: The increase in the number of cases showing delayed complications caused by HA fillers merits closer clinical attention. A thorough understanding of the patient's medical history and biopsy specimen are necessary to make a definite diagnosis and offer appropriate treatment.

Key words: complications, delayed foreign body granulomas, hyaluronic acid, orofacial region

Chin J Dent Res 2020;23(4):289–296; doi: 10.3290/j.cjdr.b867893

Intradermal injections with hyaluronic acid (HA) fillers in the orofacial region are extremely popular aesthetic procedures¹. They are frequently used to smooth out wrinkles and skin folds for facial rejuvenation and to enhance the facial features². HA is fast becoming the material of choice because of its biocompatibility and biodegradability³.

- 1 Department of Oral Pathology, Peking University School and Hospital of Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Beijing, P.R. China.
- 2 Department of Stomatology, Peking University International Hospital, Beijing, P.R. China.

Corresponding author: Dr Yan CHEN, Department of Oral Pathology, Peking University School and Hospital of Stomatology, #22 Zhongguancun South Avenue, HaiDian District, Beijing 100081, P.R. China. Tel: 86-10-82195221; Fax: 86-10-82195221. Email: 1554326447@qq.com

This work was supported by Research Grants from the National Natural Science Foundation of China (81141092 and 81302349).

HA is one of the most prevalent glycosaminoglycans in the dermis, and HA fillers are stabilised by cross-linking of HA and binding of water molecules to it². Over time they are slowly 'digested' in vivo by endogenous hyaluronidase through enzymatic degradation. Their effect usually lasts from around 6 months to 2 years³. Accordingly, patients are advised to have top-up treatments to maintain the results.

HA fillers typically have favourable safety profiles^{4,5}. The most common side effects include treatment site reactions such as swelling, bruising, redness, pain and tenderness. These generally disappear within 1 week of the injection⁶. Delayed side effects are rare.

Over the last 10 years, we encountered several patients with nodules in the orofacial region. Their pathological manifestations indicated granulomatous foreign body reaction to blue-stained material related to HA fillers. No clinicians had considered that the reaction could be related to aesthetic procedures before surgery. During follow-up, it was surprising to note that




Fig 1 Amorphous basophilic material surrounded by a large number of foreign body giant cells and macrophages, which was the pathological characteristic of HA-induced foreign body granulomas (HE, 40×), in patients 1 to 7, respectively.

patients had received HA filler injections 3 to 10 years previously. The absorbable fillers did not get absorbed by the surrounding tissues and rather caused granulomatous reactions years after the filler was injected. Therefore, we sought to determine why compatible HA fillers cause delayed foreign body granulomas, and why residual absorbable filler was still present in tissues years after it was injected.

This article summarises cases of delayed granulomatous reactions in the orofacial region following HA filler injections and discusses the potential mechanisms to help clinicians to better understand the characteristics of delayed foreign body granulomas caused by HA fillers and offer suitable treatments accordingly.

Materials and methods

Pertinent studies published in English were reviewed and a summary was drawn up of reported cases of delayed granulomatous reactions after HA injection⁷⁻¹⁸ (Table 1). According to the literature, HA-induced granulomatous reactions were characterised by amorphous basophilic material (positive with Alcian blue staining), surrounded by multinucleated giant cells and epithelioid histiocytes in the dermis and subcutaneous fat.

Next, we performed an electronic search of pathological reports dated between 2009 and 2019 from the Department of Oral Pathology at the Peking University School and Hospital of Stomatology, Beijing, China, using the keyword 'basophilic' matched with 'foreign body', and 17 cases were selected. After preliminary screening, we carefully reviewed the pathological sections of the possible cases and identified cases of foreign body granulomas caused by HA fillers based on their pathological characteristics. Two cases were excluded because their pathological manifestations were not in accordance with HA fillers. We then

obtained the complete medical records and contacted the patients for their detailed cosmetic histories and prognosis. Four cases were excluded because it was not possible to contact the patients or they refused to provide their medical histories.

Finally, a total of 11 patients who had developed delayed granulomatous reactions after receiving HA injections and underwent surgical resection in our hospital were included in the study. A retrospective chart review of the patients was conducted that included their age and sex, history of facial cosmetic procedures, symptoms, interval between the time of injection and the first visit, imaging features, treatments, pathological results and outcomes. All patients provided written informed consent for this review to be carried out.

Results

The clinical characteristics of the 11 patients are summarised in Table 2. All were women, with a mean age of 38.5 years. In most cases, the granulomas appeared as palpable nodules with slow or no growth, no pain, moderate hardness, a smooth boundary and normal mobility. The nodules had developed 3 months to 6 years before the surgery. The nodules were located in the cheeks, chin, lips or temples. Patients numbered 1, 6 and 9 underwent ultrasound examinations in other hospitals before the surgery. The lesions showed a lower echo with a definite boundary. The nodule in patient 6 was located in the mandible and was suspected by the sonographer to be a lymph node abscess.

The patients' medical histories seemed unremarkable during the first visits and the clinicians were not aware of their past cosmetic procedures. The clinicians only provided a descriptive diagnosis such as 'soft tissue nodule' before the surgery.

All patients underwent surgical removal of the nodules and histopathological examination. During surgery, the nodules had capsule walls and were filled with a yellow paste- or cheese-like substance. The pathological manifestations were characteristic. All haematoxylin and eosin-stained sections revealed amorphous basophilic material under the microscope, surrounded by a large number of foreign body giant cells and macrophages (Fig 1). However, the microscopic appearances of the basophilic materials showed minor differences. The pathological features of patients 1, 6, and 7 showed pools of amorphous basophilic material. Cells seldom traversed the pool. The pathological features of patients 4 and 5 showed blueish material with a honeycomb-like, filamentous appearance. Giant cells were numerous and scanty material was also seen in the

Prognosis	Not given	Good response	No recurrence	No symptoms	Slight improve- ment	Good esthetical results	Remission	Remission	Not given	Uncontrollable	Not given	Mild improve- ment	Resolution	Resolution, no recurrence	S =
Treatment	Excision	Punch biopsy, hyaluron- idase, triamcinolone	Excision	Excision	Punch biopsy, mino- cycline	Excision	Punch biopsy	Incisional biopsy, hyaluronidase, anti- inflammatory therapy	Biopsy	Repeated debride- ment, anti-inflammatory therapy	Betamethasone	Punch biopsy, triamci- nolone	Punch biopsy, hyaluronidase, triamcinolone	Punch biopsy, hyaluronidase	
Histopathological character- istics	Foreign body granulomas, amorphous basophilic material (AB+), dense fibrosis	Foreign body granulomas, amorphous basophilic material (AB+)	Foreign body granulomas, amor- phous basophilic material	Foreign body granulomas, amorphous basophilic sometimes eosinophilic material, fibrous capsule	Foreign body granulomas, amorphous basophilic material (AB+), vacuoles	Foreign body granulomas, two different shapes of amorphous basophilic material, vacuoles	Foreign body granulomas, amorphous basophilic material (AB+)	Foreign body granulomas, amorphous basophilic material	Foreign body granulomas, amorphous basophilic material (AB+), mucicarmine positive	Foreign body granulomas, amorphous basophilic material (AB+), colloidal iron positive	Foreign body granulomas, amorphous basophilic material (AB+)	Foreign body granulomas, amorphous basophilic material, cyst-like particles	Foreign body granulomas, amorphous basophilic material	Foreign body granulomas, amorphous basophilic material	
Clinical characteristics	Nodule	Swelling	Nodule	Multiple nodules	Multiple nodules	Nodule	Nodule	Multiple painful nodules	Nodule	Several skin ulcers	Erythematous nodules	Four nodules	Painful erythe- matous nodules	Red nodules	
Time since injection	2 y	2 y and 10 mo (two injections)	6 mo	1 y	2 mo and 2 y (multiple injec- tions)	5 y	2 y	12 y	3 mo and 18 mo (two injec- tions)	5 то	6 то	6 то	2 mo	3 mo	
Trade name and type of filler	Unknown HA filler	Juvina and Aliaxin (two different types of HA)	Unknown HA filler	Perlane	Juvederm and other unknown fillers	Two different types of HA and other unknown fillers	Restylane	Restylane	Juvederm Voluma Xc	Restylane	Restylane and collagen	Matridex (HA and dex- tranomer)	Juvederm Ultra	Unknown HA filler	
Location	Right buccal area	Right medial lower eyelid area	Upper lip	Upper and lower lips	Glabella, cheeks, naso- labial and perio- ral areas	Upper lip	Nose dorsum	Upper lip	Left mouth angle Juvederm Volum	Infraorbital zone	Glabella and periorbital area	Periorbital area	Periocular area	Horizontal lateral canthal lines	ian blue staining
Sex/ age	F/52	F/49	F/48	F/54	F/59	F/72	F/21	F/65	F/73	F/50	F/72	F/58	F/61	F/49	ith Alc
Study	Kaczorowski et al ⁷	Parulan et al ⁸	Tamiolakis et al ⁹	Alcântara et al ¹⁰	Rongioletti et al ¹¹	Rongioletti et al ¹¹	Kim et al ¹²	Curi et al ¹³	Tseng et al ¹⁴	Cecchi et al ¹⁵	Cozzani et al ¹⁶	Yang et al ¹⁷	Alsaad et al ¹⁸	Alsaad et al ¹⁸	(AB±). Positive with Alcian blue staining

(AB+): Positive with Alcian blue staining

 Table 1
 Summary of reported cases of delayed granulomatous reactions after HA injections.

1	10	9	∞	7	6	O	4	ω	2	Pelintes	Patient
F/45	F/50	F/50	F/22	F/37	F/33	F/35	F/26	F/47	F/48	F/36	Sex/ age
Right cheek	Chin	Left cheek	Chin	Left upper lip	Right man- dible	Right cheek	Both cheeks	Chin and temples	Upper lip	Right cheek	Site(s) of lesion
Palpable nodule with slow growth and no pain	Palpable nodule with slow growth and no pain	Palpable nodule with no growth or pain	Palpable nodule with no growth or pain	Palpable nodule with slow growth and pressing pain	Palpable nodule with slow growth and no pain	Palpable nodules with slow growth and no pain	Palpable nodules with slow growth and no pain	Palpable nodules with no growth or pain	Palpable nodule with no growth or pain	Palpable nodule with no growth or pain	Symptoms
3 mo	5 y	3 у	3 у	1 у	4 y	3 mo	1 y	2 y	6 mo	6 у	Duration
Nodule measuring 5 cm in diameter, smooth boundary, tough quality	Nodule measuring 2 cm in diameter, smooth boundary, soft, good mobility	Nodule measuring 1.5 cm in diameter, smooth boundary, moderate hardness	Soft nodule	Nodule measuring 1 cm in diameter, tough quality, good mobility	Nodule measuring 2 cm in diameter; soft, smooth boundary, good mobility	Nodules with moderate hardness, smooth boundary, irregular shape	Nodules measuring 1.5 cm in diameter, smooth boundary, normal mobility, tough quality	Nodule measuring 1 cm in diameter, moderate hardness	Nodule measuring 1.5 cm in diameter, tough quality, normal mobility	Nodule measuring 1.5 cm in diameter, moderate hardness, smooth boundary, normal mobility	Sex/ Site(s) of Symptoms Duration Physical examination Treatment Intraoperative find age lesion
Excision	Excision	Excision	Excision	Excision	Excision	Excision	Excision of nodules in both cheeks	Excision of nodule in chin	Excision	Excision	Treatment
Cystic nodule with pasty contents	Irregular brown soft tissue with capsule	Irregular soft tissue	Transparent jelly material without boundary	Cystic nodule and labial gland	Irregular and soft nodule with capsule and yellow cheese-like contents	Multiple nodules in right cheek with pseudocapsules	Solid nodule in right cheek with yellowish-white cross section; cystic nodule in left cheek with pasty yellow contents	Oval nodules with thin wall and pasty yellow contents	Nodule with intact envelope and yellow cheese-like contents	Light yellow cystic nodule with integrated membrane containing yellow keratin	Intraoperative findings
No recurrence or symptoms	No recurrence or symptoms	No recurrence or symptoms	No recurrence or symptoms	No recurrence or symptoms	No recurrence or symptoms	No recurrence or symptoms	No recurrence or symptoms	No recur- rence in chin but nodules retained in temples	No recurrence but pain in upper lip	No recurrence but facial asymmetry	Follow-up
Injection of HA into cheeks 10 years previ- ously	Injection of unknown fillers into chin and nasal dorsum 8 years previously	Injection of HA into cheeks 5 years previously	Injection of HA into chin 4 years previously	Injection of HA into lips 6 years previously	Injection of HA into chin 5 years previously	Injection of HA and botu- linum toxin into chin 10 years previously	Injections of botulinum toxin in both cheeks twice, 2 and 3 years previously	Injection of HA into chin and temples 10 years previously	Injection of HA into upper lip 3 years previously	Injection of unknown fillers into cheeks 10 years previously	History of facial cos- metic procedures

cytoplasm. Eosinophils were seen beside the giant cells. More vacuoles were found in the basophilic material of patients 2 and 3. Although all pathological reports included basophilic material as well as foreign body reactions, HA filler was not mentioned because the pathologists were unfamiliar with the histological pattern of HA fillers and did not know the detailed medical history of the cases during the first appointment.

During the postsurgical follow-up, we collected information about patients' detailed cosmetic histories and prognosis. All patients admitted having received injections of dermal fillers from 3 to 10 years ago. Eight of them reported that they had received HA fillers, two could not remember the nature of the filler material, and the other reported a filler substance that was inconsistent with her histological findings.

Nine of the 11 patients had a favourable prognosis with no symptoms or recurrence. One patient complained of facial asymmetry after surgery and another patient reported mild pain in their upper lip.

Discussion

A foreign body granuloma is a chronic inflammatory reaction mainly involving multinucleated giant cells and is one of the most serious complications of soft filler procedures¹⁹. The granuloma presents as firm, often mobile, subdermal or submucosal focal, bosselated or multifocal nodules that are sometimes coupled with infection and understandably have a negative effect on facial aesthetics²⁰. Their incidence ranges from 0.01% to 14% according to the different chemical nature of the injected fillers²¹. Compared with permanent materials, absorbable materials have a much lower risk of foreign body reactions¹⁰.

As a biological substance that naturally presents in the dermis without species specificity, HA should, in principle, be tolerated by all living organisms. However, HA products injected as cosmetic fillers are not the natural glycosaminoglycan found in the dermis. To avoid enzymatic degradation by endogenous hyaluronidase, cross-linking is essential to prolong the product's half-life. Regardless of whether HA is produced by engineering techniques of microbiological or avian origin, impurities are inevitable. Therefore, HA fillers can trigger an immune reaction in the human body tissue. Reports of foreign body granulomas in the orofacial region caused by HA fillers are few, especially those of delayed granulomas appearing years after the injection. According to the literature, the time between injection and the appearance of the first foreign body granuloma is usually 6 to 24 months²². In our patients,




Fig 2 The fibrous capsule around HA fillers that prevents the absorption of HA fillers into the surrounding tissues (HE, 1.25×). **(a)** Pathological manifestation of patient 3; **(b)** Pathological manifestation of patient 4.

however, the time between injection and the onset of foreign body granuloma was up to 10 years.

The mechanism and trigger factors for the sudden onset of granulomatous reactions after an uncertain delay period are not fully understood. Three possibilities have been proposed. First, biofilms on the surface of HA fillers enable persistent minimal infection with little host response. Bacteria can lie dormant for long periods and can cause granulomatous inflammation when they emerge from their planktonic state^{5,12}. Second, HA molecules or impurities could trigger immune-mediated delayed hypersensitivity reactions²³. Moreover, it has been reported that the incidence of hypersensitivity declined significantly after the purity of HA increased²⁴. Third, the disintegration of the cross-linked product may provoke an inflammatory response. Small fragments are proinflammatory whereas long chains inhibit inflammation^{6,25}. The glvcosaminoglycans may act as superantigens to activate the immune reactive cells²⁶.

Granuloma formation involves several phases: protein adsorption, macrophage adhesion, macrophage fusion and crosstalk^{19,27}. The physical properties of fillers, such as particle size, surface shape, surface charge and particle concentration, can influence phagocytosis⁵. In cases where the particle volume is greater than the macrophage volume, macrophage aggregation is required and foreign body giant cells are formed. Macrophages secrete factors that recruit and activate fibroblasts, and a fibrous capsule develops around the material that prevents the absorption of injected material into the surrounding tissues (Fig 2). Hence, HA fillers were still found several years after injection in our cases.

The clinical presentations of foreign body granulomas including single or multiple nodules or swelling lack specificity and resemble other conditions such as




Fig 3 Pathological manifestation of foreign body granulomas induced by polyacrylamide gel (HE, 10×), which needed to be distinguished from HA-induced foreign body granulomas. Polyacrylamide gel is admixed and intermingles with vacuoles and cystic spaces of variable sizes.

cysts, tumours and other chronic diseases. They usually appear as small anechoic pseudocystic structures on ultrasound and fluid attenuation that may infiltrate subcutaneous fat on computed tomography (CT) scans. It is difficult to distinguish foreign body granulomas from other cystic lesions even with the help of imaging examination⁸. Diagnosis of foreign body granulomas is challenging without establishing a history of cosmetic procedures. When a granuloma occurs weeks or months after a dermal filler injection, the patient will probably recognise the lesion as a complication of the treatment and consult with their cosmetologist for help. In delayed cases, however, patients are usually unaware of the possibility of adverse effects and omit to mention their cosmetic history. We recommend that clinicians should inquire about cosmetic history in detail when they encounter an inexplicable granuloma in the orofacial region, especially in young or middle-aged women.

Unfortunately, the exact history of filler injections was not available in most cases, particularly when the granulomas were delayed or developed in an area distant from the initial injection. Sometimes patients reported the wrong filler substances, making the diagnosis more challenging. When the exact history of filler injections is not available, histopathological study remains the gold standard for exact diagnosis and identification of the responsible filler material. Thus, oral pathologists should be familiar with the histological pattern of each filler type. With haematoxylin and eosin (HE) staining, HA fillers are microscopically characterised by amorphous basophilic material, and Alcian blue staining is positive⁶. In our patients, the microscopic appearance of the basophilic materials showed small

differences because they were from different brands of HA filler. There are now almost 200 HA products on the market⁶. Each product differs widely from the others in its manufacturing process and physical properties³. For example, biphasic HA fillers such as Restylane (Galderma, Lausanne, Switzerland) and Hylaform (Genzyme, Cambridge, MA, USA) contain a range of microsphere sizes and display a granular, filamentous or wispy morphology because of the sizing technology in the processing²⁸, whereas monophasic fillers such as Juvéderm (Allergan, Dublin, Ireland) elicit a homogenous appearance because of the Hylacross technology^{3,28}.

Among the commonly used dermal fillers including collagen, poly-L-lactic acid (PLLA), calcium hydroxylapatite (CaHA), silicon and polymethylmethacrylate (PMMA), only HA and polyacrylamide gel (PAAG) present as basophilic material under HE staining. A difficulty in the diagnosis of HA-induced foreign body granulomas is the histological differentiation between HA and PAAG. In some cosmetic advertisements, PAAG was described as a kind of permanent HA. However, they have quite different properties and must be distinguished to offer appropriate treatments. It has been said that staining with Alcian blue is strongly positive with HA and faintly positive with PAAG¹¹. Eosinophils are frequent around basophilic HA, while intense necrosis is frequent with PAAG²⁹. HA exhibits a wavy structure, while PAAG is admixed and intermingled with vacuoles and cystic spaces of variable size^{6,11}. Based on the distinguishing features of histological manifestations, we successfully identified a case of PAAG-induced foreign body granuloma in our study (Fig 3). We found that the patient with PAAG-induced foreign body granulomas had received an injection of Amazingel 12 years ago. Amazingel filler is a nonabsorbent material and is forbidden from use in China due to its high risk of adverse reactions.

After the diagnosis of HA-induced foreign body granulomas, conservative treatment should be the first choice. According to previous reports, intralesional hyaluronidase, systemic and local steroids and antibiotic therapy have been used and led to obvious improvements in patients' conditions^{8,13,18}. Among these, local steroid injection with a high dose of triamcinolone is the most common treatment. Systemic therapy can be used to treat widespread inflammatory granulomas¹⁹. When the granulomas were caused by multiple cosmetic injections and different fillers, conservative treatment may be less effective¹¹. Surgical procedures are the most suitable choice after multiple unsuccessful conservative therapies.

Most of our patients were satisfied with the outcomes of resection surgery. However, one patient complained of asymmetry of the cheeks following removal of excessive dermal and subcutaneous tissue and another complained of pain in the lip, which may have resulted from a nerve injury during surgery. These sequelae should be considered, and surgery should be avoided when possible.

The patients received dermal filler injections to enhance their facial aesthetics without surgery. However, those with foreign body granulomas did not achieve a satisfying appearance and rather suffered as a result of facial nodules and resection surgery. To avoid granuloma formation, physicians should pay attention to several aspects. First, different dermal fillers should not be injected into the same anatomical location⁵ as the interaction between the materials is unpredictable¹¹. Second, injecting fillers into the subcutaneous fat layer is considered safer than injecting them into the dermal layer³⁰, as the skin has a strong immune function and actively mounts foreign body reactions²². Third, wellknown brands with good safety profiles should be preferred as their complication rates are much lower than non-standard brands. Untested cheap products should never be used.

Conclusion

Foreign body granulomas can develop years after HA injection. The diagnosis of HA-induced foreign body granulomas was clinically challenging without the exact history of filler injections. Clinicians should inquire about patients' cosmetic history in detail when they encounter inexplicable nodules in the orofacial region, especially in young or middle-aged women. In this case, biopsy specimens are helpful. The pathologist should be familiar with the histological characteristics of different dermal fillers to offer proper diagnosis and avoid unnecessary surgery. As the popularity of cosmetic procedures grows, the occurrence of complications associated with injectable fillers is also expected to increase. This article may increase clinicians' awareness of these complications and help them select the appropriate therapy.

Acknowledgements

We thank the patients for their cooperation.

Conflicts of interest

The authors declare no conflicts of interest related to this study.

Author contribution

Dr Fang Fei ZHANG collected the data and drafted the manuscript; Dr Zhi Xiu XU performed the pathological examinations; Dr Yan CHEN designed the study and revised the manuscript. All authors approved the final manuscript.

(Received Jan 28, 2020; accepted Jun 18, 2020)

References

- The American Society for Aesthetic Plastic Surgery. Cosmetic Surgery National Data Bank Statistics. Aesthet Surg J 2018;38:1–24.
- Gutowski KA. Hyaluronic acid fillers: science and clinical uses. Clin Plast Surg 2016;43:489–496.
- 3. Mansouri Y, Goldenberg G. Update on hyaluronic acid fillers for facial rejuvenation. Cutis 2015;96:85–88.
- Dayan SH. Complications from toxins and fillers in the dermatology clinic: recognition, prevention, and treatment. Facial Plast Surg Clin North Am 2013;21:663–673.
- DeLorenzi C. Complications of injectable fillers, part I. Aesthet Surg J 2013;33:561–575.
- Haneke E. Adverse effects of fillers and their histopathology. Facial Plast Surg 2014;30:599

 –614.
- Kaczorowski M, Nelke K, Łuczak K, Hałoń A. Filler migration and florid granulomatous reaction to hyaluronic acid mimicking a buccal tumor. J Craniofac Surg 2020;31:e78–e79.
- Parulan MAA, Sundar G, Lum JH, Ramachandran U. A case report on dermal filler-related periorbital granuloma formation. Orbit 2019;38:169–172.
- Tamiolakis P, Piperi E, Christopoulos P, Sklavounou-Andrikopoulou
 A. Oral foreign body granuloma to soft tissue fillers. Report of two
 cases and review of the literature. J Clin Exp Dent 2018;10:e177–
 e184.
- Alcântara CEP, Noronha MS, Cunha JF, Flores IL, Mesquita RA. Granulomatous reaction to hyaluronic acid filler material in oral and perioral region: a case report and review of literature. J Cosmet Dermatol 2018;17:578–583.
- Rongioletti F, Atzori L, Ferreli C, et al. Granulomatous reactions after injections of multiple aesthetic micro-implants in temporal combinations: a complication of filler addiction. J Eur Acad Dermatol Venereol 2015;29:1188–1192.
- Kim JH, Choi JS, Yun JH, et al. Foreign body reaction to injectable hyaluronic acid: late granuloma formation. Ann Dermatol 2015;27:224–225.
- Curi MM, Cardoso CL, Curra C, Koga D, Benini MB. Late-onset adverse reactions related to hyaluronic acid dermal filler for aesthetic soft tissue augmentation. J Craniofac Surg 2015;26:782–784.
- Tseng CH, Wang YP, Chen HM, Chang JYF. Hyaluronic acid injection-induced delayed-onset foreign body granuloma. J Dent Sci 2015;10:341–343.
- Cecchi R, Spota A, Frati P, Muciaccia B. Migrating granulomatous chronic reaction from hyaluronic acid skin filler (Restylane): review and histopathological study with histochemical stainings. Dermatology 2014;228:14–17.
- Cozzani E, Rongioletti F, Santoro F, Rebora A, Parodi A. Can ultraviolet rays induce a granulomatous reaction after hyaluronic acid dermal filler injections? Int J Dermatol 2013;52:1432–1434.
- Yang JH, Lee SM, Won CH, et al. Foreign body granuloma caused by hyaluronic acid/dextranomer microsphere filler injection. Int J Dermatol 2012;51:1517–1518.

- Alsaad SM, Fabi SG, Goldman MP. Granulomatous reaction to hyaluronic acid: a case series and review of the literature. Dermatol Surg 2012;38:271–276.
- Lee JM, Kim YJ. Foreign body granulomas after the use of dermal fillers: pathophysiology, clinical appearance, histologic features, and treatment. Arch Plast Surg 2015;42:232–239.
- Eversole R, Tran K, Hansen D, Campbell J. Lip augmentation dermal filler reactions, histopathologic features. Head Neck Pathol 2013;7:241–249.
- Rongioletti F. Exogenous cutaneous deposits with special consideration to skin reactions to soft-tissue fillers. In: Smoller BR, Rongioletti F (eds). Clinical and Pathological Aspects of Skin Diseases in Endocrine, Metabolic, Nutritional and Deposition Disease. Berlin/Heidelberg: Springer Science+Business Media, 2010:181–189.
- Lemperle G, Gauthier-Hazan N, Wolters M, Eisemann-Klein M, Zimmermann U, Duffy DM. Foreign body granulomas after all injectable dermal fillers: part 1. Possible causes. Plast Reconstr Surg 2009;123:1842–1863.
- Homsy A, Rüegg EM, Jandus P, Pittet-Cuénod B, Modarressi A. Immunological reaction after facial hyaluronic acid injection. Case Reports Plast Surg Hand Surg 2017;4:68–72.

- Friedman PM, Mafong EA, Kauvar AN, Geronemus RG. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg 2002;28:491–494.
- Mummert ME. Immunologic roles of hyaluronan. Immunol Res 2005;31:189–206.
- Bitterman-Deutsch O, Kogan L, Nasser F. Delayed immune mediated adverse effects to hyaluronic acid fillers: report of five cases and review of the literature. Dermatol Reports 2015;7:5851.
- 27. Christensen L. Normal and pathologic tissue reactions to soft tissue gel fillers. Dermatol Surg 2007;33 Suppl 2:S168–S175.
- Fried I, Pincus LB, North J, El-Shabrawi-Caelen L. Basal cell carcinoma with a bonus. J Cutan Pathol 2011;38:261–263.
- Parada MB, Michalany NS, Hassun KM, Bagatin E, Talarico S. A histologic study of adverse effects of different cosmetic skin fillers. Skinmed 2005;4:345–349.
- Lee SC, Kim JB, Chin BR, Kim JW, Kwon TG. Inflammatory granuloma caused by injectable soft tissue filler (Artecoll). J Korean Assoc Oral Maxillofac Surg 2013;39:193–196.